Advancements in Mental Health Treatments: NRx Pharmaceuticals and Cybin Inc. Acquisitions and Developments

Cybin Inc. Chief Business Officer to Speak at H.C. Wainwright Conference

Fireside Chat with Cybin Inc.'s CMO at Cantor Global Healthcare Conference

Leadership Changes and Treatment Advancements in Mental Health Companies

Advancing Psilocybin Therapy: Psylutions Supports Rescheduling Efforts

Empowering Growth for Ketamine & TMS Clinics: Strategic Partnership Announcement

Cybin Inc. Receives Approval for Phase 3 Study of CYB003 in Australia

NRx Pharmaceuticals Urges FDA to Ban Benzethonium Chloride from Ketamine Products

Advancements in Incannex Healthcare Inc.: Positive Phase 2 Results and Strong Valuation Potential

Cybin Inc. Reports Promising Results and Shareholder Meeting Summary

Cybin Inc. Reports Q1 2025 Results and Progress in Depression and Anxiety Studies

NRx Pharmaceuticals' HOPE Therapeutics(TM) Expands Network and Expertise with Acquisition of Dura Medical LLC

Cybin Inc. Receives European Approval for Phase 3 Study on CYB003 for Major Depressive Disorder

Revolutionizing Mental Healthcare: Cybin's CEO to Speak at Growth Conference

Exploring Neuroplasticity in CNS Disorders with NRx Pharmaceuticals CEO

Cybin Inc. Receives UK Approval for Phase 3 Trial in Depression

NRx Pharmaceuticals Applies for FDA Priority Voucher for NRX-100

Advancing FDA-Designated Therapies: NRx Pharmaceuticals Collaborates with IBN for Corporate Communications Strategy

Psyence Biomedical Chief to Speak at Psychedelic Science 2025 Conference

Advancements in Cybin Inc.'s Phase 3 Psychedelic Therapeutics Program